Sharing my story helps raise awareness about pulmonary fibrosis
For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.| Pulmonary Fibrosis News
For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.| Pulmonary Fibrosis News
Trevi Therapeutics plans to launch two Phase 2 clinical trials testing Haduvio for chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Trevi has launched a Phase 2b clinical trial to test Haduvio for the treatment of chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
The FDA application followed trial results that showed NP-120 (ifenprodil) was well tolerated for idiopathic pulmonary fibrosis with cough.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for IPF, may stabilize lung function, according to an interim analysis of an ongoing trial.| Pulmonary Fibrosis News
Columnist Sam Kirton talks to Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation, about the need for better research.| Pulmonary Fibrosis News
Columnist Sam Kirton takes readers on his journey from a pulmonary function test to his results from lung biopsies that weren't routine.| Pulmonary Fibrosis News
There are more immune NK T-cells in the lungs of people with idiopathic pulmonary fibrosis than in healthy people, research shows| Pulmonary Fibrosis News
Margarida Maia is a science writer for Pulmonary Fibrosis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of pulmonary fibrosis topics.| Pulmonary Fibrosis News
Columnist Sam Kirton finds that filling the silence is part of living with a chronic condition, especially amid retirement and COVID-19.| Pulmonary Fibrosis News
Inconsistent results of NXP002, a new formulation of tranilast, delayed completion of the package needed for potential clinical trials.| Pulmonary Fibrosis News
Treatment with Nuformix's experimental therapy NXP002 reduced markers of fibrosis in a laboratory model of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Category archive page for News.| Pulmonary Fibrosis News
Vanda Pinto is a science writer for Pulmonary Fibrosis News with a PhD in biomedicine. She covers the latest news and information on a variety of pulmonary fibrosis topics.| Pulmonary Fibrosis News
Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.| Pulmonary Fibrosis News
In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.| Pulmonary Fibrosis News
GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells to treat IPF.| Pulmonary Fibrosis News
An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded orphan drug status.| Pulmonary Fibrosis News
